Recently, IL-6 and some components involved in IL-6/STAT3 pathway are considered as the therapeutic targets, because the inhibition of IL-6/STAT3 pathway may attenuate the HCC cell survival upon IL-6 production [60]. This evidence concerns the gene IL6 and hepatocellular carcinoma.